AWA
MCRB icon

Arete Wealth Advisors’s Seres Therapeutics MCRB Stock Holding History

Arete Wealth Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,045
Closed -$15K – 785
2025
Q1 		$15K Hold
1,045
– – ﹤0.01% 713
2024
Q4 		$17K Sell
1,045
-5
-0.5% -$81 ﹤0.01% 741
2024
Q3 		$20K Sell
1,050
-58
-5% -$1.18K ﹤0.01% 696
2024
Q2 		$16K Buy
+1,108
New +$18.5K ﹤0.01% 717
2024
Q1 		– Sell
-1,235
Closed -$34.6K – 584
2023
Q4 		$34.6K Sell
1,235
-10
-0.8% -$263 ﹤0.01% 723
2023
Q3 		$59.3K Buy
1,245
+620
+99% +$47.3K 0.01% 477
2023
Q2 		$60K Buy
+625
New +$68K 0.01% 642

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Arete Wealth Advisors's MCRB Position: Q2 2025 in Review

Arete Wealth Advisors sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 1,045 shares — an estimated $15K sold.

Arete Wealth Advisors first reported a position in MCRB in Q2 2023 and held it in 7 quarters. The position peaked at $60K in Q2 2023. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • Arete Wealth Advisors reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Arete Wealth Advisors sold 1,045 Seres Therapeutics shares in Q2 2025, an estimated $15K.
  • Arete Wealth Advisors first reported a position in Seres Therapeutics in Q2 2023 and held it in 7 quarters.
  • Arete Wealth Advisors's Seres Therapeutics position peaked at $60K in Q2 2023.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on Arete Wealth Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.